Advancedbiotechnology
Pharmacogenomics
Overview
Pharmacogenomics studies how genetic variation affects drug response: metabolism (CYP2D6, CYP2C19, TPMT), targets, and immune reactions (HLA-B57:01/abacavir, HLA-B15:02/carbamazepine). Poor vs ultrarapid metabolizers need different doses; testing prevents toxicity and failure. CPIC guidelines and FDA labels now cover 100+ drug-gene pairs; preemptive panel testing is the future.
Learning objectives
- Explain CYP2D6 metabolizer phenotypes
- Describe HLA-drug hypersensitivity examples
- Explain TPMT/thiopurine dosing
- Discuss implementation challenges
CYP metabolism
CYP2D6 metabolizes ~25% of drugs (antidepressants, opioids, tamoxifen): poor metabolizers (no function) risk toxicity; ultrarapid metabolizers (gene duplications) get no effect or, with codeine, morphine overdose in children. CYP2C19 affects clopidogrel activation: poor metabolizers need alternatives after stenting.
CYP2D6 ultrarapid-metabolizer children given codeine made lethal morphine levels: FDA boxed warning, PGx in action.
HLA hypersensitivity
HLA-B57:01 + abacavir -> hypersensitivity syndrome (screening eliminated it). HLA-B15:02 + carbamazepine -> Stevens-Johnson syndrome in Southeast Asians (screening standard there). These are immune, not metabolic: the drug alters HLA-presented peptides.
HLA risk alleles concentrate in ancestries: testing must follow the patient's background.
TPMT and thiopurines
TPMT methylates thiopurines (azathioprine, 6-MP for leukemia/IBD): poor metabolizers suffer fatal myelosuppression on standard doses. Genotype-guided dosing is a textbook PGx success: test first, dose safely. NUDT15 matters additionally in Asians.
Guidelines mandate TPMT/NUDT15 testing: the clearest 'genotype or harm' case in medicine.
Implementation
CPIC guidelines translate genotypes to prescribing; FDA labels include PGx for 100+ drugs; preemptive panels (tested once, used for life) beat reactive testing. Barriers: clinician education, EHR integration, reimbursement, and evidence thresholds for each pair.
Germline PGx variants never change: preemptive panels amortize one test across decades of prescribing.
Key points
- CYP2D6/CYP2C19 variation alters drug activation and clearance
- HLA alleles predict severe immune drug reactions (abacavir, carbamazepine)
- TPMT testing prevents thiopurine toxicity
- CPIC guidelines + preemptive panels are bringing PGx to the clinic
Common misconceptions
✓ Truth: Mostly it means dosing/selecting existing drugs by genotype; truly bespoke drugs are rare.
✓ Truth: Response is polygenic plus environmental; single genes dominate only the strongest pairs.
Practice questions
Q1. CYP2D6 ultrarapid metabolizers given codeine risk
- No effect
- Morphine toxicity from rapid conversion
- Allergy
- Nothing
Excess conversion to morphine caused pediatric deaths: boxed warning.
Q2. HLA-B*57:01 screening prevents hypersensitivity to
- Penicillin
- Abacavir
- Aspirin
- Insulin
Prospective screening eliminated abacavir hypersensitivity.
Q3. TPMT testing before thiopurines prevents
- Liver growth
- Fatal myelosuppression in poor metabolizers
- Hair loss only
- Nothing
Poor metabolizers accumulate toxic thioguanine nucleotides.
Click a question to reveal the answer and explanation.
Frequently asked questions
Why does tamoxifen need CYP2D6?
Tamoxifen is a prodrug activated by CYP2D6 to endoxifen: poor metabolizers get less benefit.
What is the CPIC?
Clinical Pharmacogenetics Implementation Consortium: writes genotype-to-prescription guidelines.
Do PGx variants change over life?
Germline variants don't; but phenoconversion (drug interactions, disease) can override genotype.